
Senator Ron Wyden presses FDA and DEA on generic Adderall shortage
Sen. Ron Wyden (D-OR) is putting pressure on regulators to address an ongoing shortage of amphetamine mixed salts, a generic form of Adderall that treats ADHD.
The senator said in letters last week to DEA Administrator Anne Milgram and FDA Commissioner Robert Califf that he is “deeply disappointed on behalf of the Oregonians I represent” over the agencies’ response to the shortage.
“While I appreciate that your staff followed up with more information on the role the Center for Drug Evaluation and Research (CDER) plays in preventing and mitigating drug shortages, it falls short of the statement and actions needed. Specifically, the process is muddy and obscure as to how generic manufacturers are navigating the process to request a quota increase, and the fact that your agency does not seek out or report regional data is a grave concern,” the letter said.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.